Skip to content

Irreversible Electroporation (IRE) for the treatment of focal liver, kidney and lung cancer ablation: a pilot study

Irreversible Electroporation (IRE) for the treatment focal liver, kidney and lung cancer ablation: a pilot study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12611000937910
Acronym
IRE study
Enrollment
40
Registered
2011-08-31
Start date
2008-11-10
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

In cases where patients have inoperable tumours, direct destruction of focal tumours using various energy sources such as heat (radiofrequency ablation, microwaves), cold (cryotherapy) or ethanol injection have been used for the last twenty years. A needle is placed into the tumour under image guidance in a similar way to taking a biopsy. The energy used, heat or cold, destroys the tumour. Currently not all inoperable tumours can be treated in this way because tumours may lie close to vital structures that may be affected and therefore pose a large risk to patients. The new technology, irreversible electroporation, does not use heat or cold and therefore spares vital structures. Direct electrical current is used to destroy the outer membrane of the tumour cells. We are testing the safety and effectiveness of this form of ablation.

Interventions

The intervention is ablation using Irreversible electroporation (direct current) which disrupts the cell membrane killing the tumour cells. The whole procedure takes between 2 to 3 hours. Once the needle electrodes are in place the ablation takes approximately one minute. Depending on the size of the tumour the needle electrodes may be repositioned and further ablations (2 to approximately 10) may be performed. If complete ablation is not achieved a second procedure can be performed.

Sponsors

The Alfred Hospital
Lead SponsorHospital

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
35 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

Ages 35-85 years, Signed informed consent, Failed conventional treatment, Ability to visualize cancer foci adequately on imaging.

Exclusion criteria

Patients not deemed suitable for ablation procedure.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026